p.63 抽出テキスト

165. Sidik NP, McEntegart M, Roditi G, et al. Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study. Am Heart J 2020; 221: 48-59. PMID: 31911341 166. Handberg EM, Merz CNB, Cooper-Dehoff RM, et al. Rationale and design of the Women’s Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. Am Heart J 2021; 237: 90-103. PMID: 33745898 167. Odaka Y, Takahashi J, Tsuburaya R, et al. Plasma concentration of serotonin is a novel biomarker for coronary microvascular dysfunction in patients with suspected angina and unobstructive coronary arteries. Eur Heart J 2017; 38: 489-496. PMID: 27694191 168. Okumura K, Yasue H, Matsuyama K, et al. Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. J Am Coll Cardiol 1988; 12: 883-888. PMID: 3047196 169. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/ CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 144: e368-e454. PMID: 34709879 170. AlBadri A, Sharif B, Wei J, et al. Intracoronary Bolus Injection Versus Intravenous Infusion of Adenosine for Assessment of Coronary Flow Velocity Reserve in Women With Signs and Symptoms of Myocardial Ischemia and No Obstructive Coronary Artery Disease. JACC Cardiovasc Interv 2018; 11: 2125-2127. PMID: 30336817 171. Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018; 39: 840-849. PMID: 29293969 172. Vermeltfoort IA, Bondarenko O, Raijmakers PG, et al. Is subendocardial ischaemia present in patients with chest pain and normal coronary angiograms? A cardiovascular MR study. Eur Heart J 2007; 28: 1554-1558. PMID: 17504803 173. Shufelt CL, Thomson LE, Goykhman P, et al. Cardiac magnetic resonance imaging myocardial perfusion reserve index assessment in women with microvascular coronary dysfunction and reference controls. Cardiovasc Diagn Ther 2013; 3: 153-160. PMID: 24282764 174. Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation 2015; 131: 19-27. PMID: 25400060 175. Taqueti VR, Shaw LJ, Cook NR, et al. Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with severely impaired coronary flow reserve, not obstructive disease. Circulation 2017; 135: 566-577. PMID: 27881570 176. Driessen RS, Danad I, Stuijfzand WJ, et al. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. J Am Coll Cardiol 2019; 73: 161-173. PMID: 30654888 177. Danad I, Raijmakers PG, Driessen RS, et al. Comparison of coronary CT angiography, SPECT, PET, and hybrid imaging for diagnosis of ischemic heart disease determined by fractional flow reserve. JAMA Cardiol 2017; 2: 1100-1107. PMID: 28813561 178. Patel KK, Spertus JA, Chan PS, et al. Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a survival benefit from early revascularization. Eur Heart J 2020; 41: 759-768. PMID: 31228200 179. Bom MJ, van Diemen PA, Driessen RS, et al. Prognostic value of [15O] H2O positron emission tomography-derived global and regional myocardial perfusion. Eur Heart J Cardiovasc Imaging 2020; 21: 777- 786. PMID: 31620792 180. Gupta A, Taqueti VR, van de Hoef TP, et al. Integrated noninvasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. Circulation 2017; 136: 2325-2336. PMID: 28864442 181. Kato S, Saito N, Nakachi T, et al. Stress perfusion coronary flow reserve versus cardiac magnetic resonance for known or suspected CAD. J Am Coll Cardiol 2017; 70: 869-879. PMID: 28797357 182. Indorkar R, Kwong RY, Romano S, et al. Global coronary flow reserve measured during stress cardiac magnetic resonance imaging is an independent predictor of adverse cardiovascular events. JACC Cardiovasc Imaging 2019; 12: 1686-1695. PMID: 30409558 183. Zorach B, Shaw PW, Bourque J, et al. Quantitative cardiovascular magnetic resonance perfusion imaging identifies reduced flow reserve in microvascular coronary artery disease. J Cardiovasc Magn Reson 2018; 20: 14. PMID: 29471856 184. Sicari R, Rigo F, Cortigiani L, et al. Additive prognostic value of cor-

onary flow reserve in patients with chest pain syndrome and normal or near-normal coronary arteries. Am J Cardiol 2009; 103: 626-631. PMID: 19231324 185. Mygind ND, Michelsen MM, Pena A, et al. Coronary microvascular

function and cardiovascular risk factors in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study. J Am Heart Assoc 2016; 5: e003064. PMID: 27068634 186. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23: 2900-2902. PMID: 15860848 187. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020; 17: 503-522. PMID: 32218531 188. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134: 75-82. PMID: 17636329 189. Jensen SA, Hasbak P, Mortensen J, et al. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010; 28: 5280-5286. PMID: 21079148 190. Lestuzzi C, Vaccher E, Talamini R, et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Ann Oncol 2014; 25: 1059-1064. PMID: 24558023 191. Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53: 3028-3033. PMID: 8391384 192. Cwikiel M, Eskilsson J, Wieslander JB, et al. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 1996; 10: 805-18; discussion 819. PMID: 9813641 193. Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation 2011; 124: 1774-1782. PMID: 22007100 194. Otsu K, Tajiri K, Sakai S, et al. Vasospastic angina following immune checkpoint blockade. Eur Heart J 2020; 41: 1702. PMID: 31697341 195. Sueta D, Suyama K, Sueta A, et al. Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction. Atherosclerosis 2017; 260: 116-120. PMID: 28390289 196. Polk A, Vaage-Nilsen M, Vistisen K, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013; 39: 974-984. PMID: 23582737 197. Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58: 487-493. PMID: 16418875 198. Zafar A, Drobni ZD, Lei M, et al. The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. PLoS One 2022; 17: e0265767. PMID: 35390017 199. Goto K, Yasue H, Okumura K, et al. Magnesium deficiency detected by intravenous loading test in variant angina pectoris. Am J Cardiol 1990; 65: 709-712. PMID: 2316451 200. Miwa K, Igawa A, Miyagi Y, et al. Importance of magnesium deficiency in alcohol-induced variant angina. Am J Cardiol 1994; 73: 813-816. PMID: 8160621 201. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7: 149-156. PMID: 16455479 202. Yasue H, Mizuno Y, Harada E. Coronary artery spasm Clinical features, pathogenesis and treatment. Proc Jpn Acad Ser B Phys Biol Sci 2019; 95: 53-66. PMID: 30745502 203. Hill BG, Bhatnagar A. Beyond reactive oxygen species: Aldehydes as arbitrators of alarm and adaptation. Circ Res 2009; 105: 1044-1046. PMID: 19926880 204. Singh S, Brocker C, Koppaka V, et al. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic Biol Med 2013; 56: 89-101. PMID: 23195683 205. Chen CH, Budas GR, Churchill EN, et al. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008; 321: 1493-1495. PMID: 18787169 206. Chen CH, Ferreira JC, Gross ER, et al. Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev 2014; 94: 1-34. PMID: 24382882 207. Takeuchi F, Yokota M, Yamamoto K, et al. Genome-wide association study of coronary artery disease in the Japanese. Eur J Hum Genet 2012; 20: 333-340. PMID: 21971053 208. Gu JY, Li LW. ALDH2 Glu504Lys polymorphism and susceptibility to coronary artery disease and myocardial infarction in East Asians: a meta-analysis. Arch Med Res 2014; 45: 76-83. PMID: 24333098 209. Mizuno Y, Morita S, Harada E, et al. Alcohol flushing and positive

ethanol patch test in patients with coronary spastic angina: possible role of aldehyde dehydrogenase 2 polymorphisms. Intern Med 2013; 52: 2593-2598. PMID: 24292747